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What is already known about the topic?
•• Pain is not adequately controlled in all patients with advanced cancer.
•• There are no universally used guidelines for the treatment of pain in patients with advanced cancer.
•• Not all guideline recommendations are evidence-based.
Practice review: Evidence-based and  
effective management of pain in patients  
with advanced cancer
Emma J Chapman1 , Zoe Edwards1 , Jason W Boland2 ,  
Matthew Maddocks3, Lucy Fettes3 , Catherine Malia4,  
Matthew R Mulvey1  and Michael I Bennett1
Abstract
Background: Pain of a moderate or severe intensity affects over half of patients with advanced cancer and remains undertreated in 
at least one-third of these patients.
Aim: The aim of this study was to provide a pragmatic overview of the evidence supporting the use of interventions in pain management 
in advanced cancer and to identify where encouraging preliminary results are demonstrated but further research is required.
Design: A scoping review approach was used to examine the evidence supporting the use of guideline-recommended interventions 
in pain management practice.
Data sources: National or international guidelines were selected if they described pain management in adult cancer patients and 
were written within the last 5 years in English. The Cochrane Database of Systematic Reviews (January 2014 to January 2019) was 
searched for ‘cancer’ AND ‘pain’ in the title, abstract or keywords. A MEDLINE search was also made.
Results: A strong opioid remains the drug of choice for treating moderate or severe pain. Bisphosphonates and radiotherapy are also 
effective for cancer-related bone pain. Optimal management requires a tailored approach, support for self-management and review 
of treatment outcomes. There is likely a role for non-pharmacological approaches. Paracetamol should not be used in patients taking 
a strong opioid to treat pain. Cannabis-based medicines are not recommended. Weak opioids, ketamine and lidocaine are indicated 
in specific situations only.
Conclusion: Interventions commonly recommended by guidelines are not always supported by a robust evidence base. Research is 
required to evaluate the efficacy of non-steroidal anti-inflammatory drugs, anti-convulsants, anti-depressants, corticosteroids, some 
invasive anaesthetic techniques, complementary therapies and transcutaneous electrical nerve stimulation.
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Introduction
Pain is of a moderate or severe intensity in more than half of 
patients with advanced cancer1 and is undertreated in 
around one-third of cases.2 Poorly controlled pain is the most 
common cause for community-based cancer patients to con-
tact out-of-hours primary care services 3 and is one of the 
most frequent reasons for their hospitalisation.4 Although 
home is the preferred place of care and death for many 
patients,5 national surveys show that this is where pain con-
trol is poorest.6 However, accessing specialist palliative care 
improves pain management for patients living at home.7
There are no standardised guidelines for the manage-
ment of pain in patients with advanced cancer and not all 
guideline recommendations are evidence-based. We set out 
to provide a pragmatic overview of the state of science sup-
porting approaches commonly recommended by key guide-
lines rather than produce a novel consensus guideline. We 
also identified where encouraging preliminary results have 
been demonstrated but further research is required before 
the routine use of the practice can be recommended.
Methods
This practice review, guided by scoping review methodol-
ogy,8,9 was used to determine the extent of the evidence 
supporting the use of interventions in the management of 
pain in patients with advanced cancer. Guidelines from 
national or international bodies were selected if they 
described the management of pain in adult cancer patients 
and were written within the last 5 years in English language 
(Table 1). The Cochrane Database of Systematic Reviews 
(January 2014 to January 2019) was searched for the terms 
‘cancer’ AND ‘pain’ in the title, abstract or keywords. After 
independent screening by two researchers, 19 articles were 
identified as relevant to this review. An additional search of 
MEDLINE was made for further key publications that pro-
vided additional primary data to add to the evidence base 
for the interventions considered in Table 1 (search date: 31 
May 2019). Methods were compliant with the Preferred 
Reporting Items for Systematic reviews and Meta-Analyses 
extension for Scoping Reviews (PRISMA-ScR) Checklist 
(Supplementary Material 1). We determined the strength of 
evidence for commonly recommended interventions plus 
some non-pharmacological approaches for which there is 
currently limited evidence but a low potential for harm. 
Each intervention was then allocated to a practice recom-
mendation category of ‘Do’, ‘Do not’ or ‘Don’t know’ based 
on the direction and strength of the supporting evidence 
(Table 2). A ‘strong’ recommendation was made where 
there was evidence from a large and consistent body of evi-
dence, such as a systematic review, a ‘moderate’ recom-
mendation was made in light of solid empiric evidence from 
one or more papers and a ‘tentative’ recommendation 
where there was limited empiric evidence. Where ‘tenta-
tive’ evidence supports use of an intervention, the likely 
increased risk to the patient is considered (Table 3).
Practice recommendations – ‘Do’
Screen for pain at every engagement with a healthcare pro-
fessional. All guidelines examined recommend that patients 
should be screened for pain10–15,17 and at every engagement 
with a healthcare professional.10 Meta-analysis shows that 
What this paper adds?
•• We provide a pragmatic overview of the current ‘state of the science’ supporting pain management practice.
•• ‘Do’ and ‘Do not’ practice recommendations are made based upon a set of strength recommendations, that is, strong: 
a large and consistent body of evidence, such as a systematic review, moderate: solid empiric evidence from one or 
more papers and tentative: limited empiric evidence, a strong recommendation cannot be made.
•• Interventions are categorised as ‘Don’t know’ where there is currently a lack or paucity of high-quality empiric evidence 
to support the approach in management of cancer pain but some evidence to suggest that the approach is effective in 
a non-cancer context. These are interventions where further research is required before the routine use of the practice 
can be recommended.
Implications for practice, theory or policy
•• An oral strong opioid remains the drug of choice for treating moderate or severe pain in patients with advanced cancer 
and should be supplemented with bisphosphonates and/or radiotherapy for bone pain. Optimal management requires 
a tailored approach, support for self-management and regular review of treatment outcomes. There is likely a role for 
non-pharmacological approaches.
•• Oral paracetamol should not routinely be used for patients who are already taking a strong opioid to treat moderate-to-
severe pain. Cannabis-based medicines are not recommended. Weak opioids, ketamine and lidocaine are only indicated 
in specific situations.
•• Further research is required into the use of non-steroidal anti-inflammatory drugs, anti-convulsants, anti-depressants, 
corticosteroids, some invasive anaesthetic techniques, acupuncture, massage and transcutaneous electrical nerve 
stimulation.
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using patient-reported measurements of pain reduces pain 
intensity in cancer patients perhaps by prompting discus-
sion about symptoms between patient and professional.18 
A large, randomised trial found that integration of a sys-
tematic bedside pain assessment tool into cancer care 
improves pain outcomes.19































































































Standards for the management of cancer-related pain across 
Europe – a position paper from the EFIC Task Force on cancer 
pain (2019)10
 
National Clinical Practice Guidelines in Oncology (NCCN 
Guidelines®) – adult cancer pain (Version 2. 2019)11
 
Scottish Palliative Care Guidelines – pain management 
(updated 2019)12
 
Management of cancer pain in adult patients: European 
Society for Medical Oncology (ESMO) Clinical Practice 
Guidelines (2018)13  
Pharmacotherapy of pain in cancer patients. 
Recommendations of the Polish Association for the Study of 
Wordliczek et al. (2018)14  
World Health Organization (WHO) Guidelines for the 
pharmacological and radiotherapeutic management of cancer 
pain in adults and adolescents (2018)15  
Spanish Society of Medical Oncology (SEOM, 2017)16
 
Pharmacological management of cancer pain in adults. 
National Clinical Guideline No. 9 (Ireland, 2015)17
 
Shaded box shows where intervention is included in the guideline.
Table 2. How categories of recommendation were decided.
Do High-quality published evidence for effectiveness in pain management in cancer patients
AND
Clear favourable benefit to risk ratio
Do not Evidence that the approach is not effective in pain management in cancer patients
OR
Lack of high-quality evidence to support its use
AND
Unfavourable benefit to risk balance
Don’t know High-quality published data to support its use in the management of pain in a context 
other than advanced cancer
AND/OR
Limited evidence for effectiveness in pain in cancer patients, further research is required
Strength of recommendations
Strong A large and consistent body of evidence, such as a systematic review
Moderate Solid empiric evidence from one or more papers
Tentative Limited empiric evidence
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Assess the components of the pain. It is widely recom-
mended that assessment should include classification of 
the type and pathophysiology of the pain.10–14 Aetiology, 
mechanisms and impact of cancer pain should be evalu-
ated and this information used to inform the treatment 
plan.10 Identification and grading20 of neuropathic pain 
are of particular importance as it is a predictor of poor 
pain management outcome in cancer patients.21 A tenta-
tive recommendation is made due to the potential ben-
efit and low risk of harm yet a lack of high-quality 
evidence to support a role for pain assessment in increas-
ing efficacy of treatment.
Agree upon a tailored pain management plan
Treat moderate or severe pain with a strong opioid.  
Morphine remains the first-line treatment for moder-
ate-to-severe cancer pain; all commonly used oral or 
transdermal opioids have similar efficacy.22,23 How-
ever, less than half of patients who die of cancer are 
prescribed a strong opioid, and this occurs around 
median 9 weeks before death.24–26 Patients with inad-
equately managed pain may benefit from referral to 
specialist palliative care at an early stage, as a longer 
duration of specialist palliative care is associated with 
increased access to opioids and improved quality of 
life indicators.27
Consider opioid switching. Switching to an alternative 
opioid28–32 is recommended if there is inadequate pain 
relief or unacceptable side effects.11,12,13,14,16,17 Evidence to 
support opioid switching is of moderate strength, better 
pain relief or reduced side effects were reported in 50% 
of patients who switched due to sub-optimal response to 
another opioid in a recent four-arm, phase-IV randomised 
controlled trial (RCT).33 Of note, methadone has similar 
analgesic actions as morphine34 but a long and unpredict-
able plasma half-life, which can lead to problems with 
accumulation and toxicity. Methadone should only be 
used for cancer pain under the guidance of specialist pal-
liative care professionals.
Consider epidural or intrathecal opioids. Spinal or epi-
dural administration of opioids or implanted intrathecal 
pumps is advocated.10,11,13,14,16,17 The evidence to support 
this from two RCTs is judged as moderate, the complexity of 
running trials in this group of patients is acknowledged.35–37 
Implantation of a spinal opioid infusion requires access to 
a specialist pain management team for ongoing review and 
follow-up and careful consideration of fitness to undergo 
the procedure in patients with end-stage cancer.
Treat metastatic bone pain with radiotherapy, bis-
phosphonates or both. Metastatic bone pain can be 
Table 3. Summary of recommendations for addressing pain in advanced cancer patients.
Strength of evidence
Do
 1. Screen for pain Strong
 2. Assess the components of the pain (e.g. neuropathic, nociceptive, inflammatory) Tentative
 3. Agree upon a tailored pain management plan
  (a) Treat moderate or severe pain with a strong opioid, such as morphine Strong
  (b) Consider opioid switching Moderate
  (c) Consider epidural or intrathecal administration of opioids Moderate
  (d) Treat metastatic bone pain with radiotherapy and/or bisphosphonates Strong
  (e) Support patients to use self-management strategies Strong
  (f) Physiotherapy-based interventions Tentative
  (g) Non-pharmacological approaches, for example, music therapy Tentative
 4. Regularly review and evaluate cancer pain treatment outcomes Moderate
Do not
 1. Routinely use oral paracetamol to treat moderate or severe pain in patients on strong opioids Moderate
 2. Routinely use weak opioids such as codeine Moderate
 3. Routinely use ketamine Moderate
 4. Routinely use intravenous lidocaine Moderate
 5. Use cannabis-based medicines Strong
Don’t know if there is benefit of
 1. Non-steroidal anti-inflammatory drugs
 2. Anti-convulsants, anti-depressants
 3. Corticosteroids
 4. Other anaesthetic interventions, such as coeliac plexus block and spinal cord stimulation
 5. Acupuncture, massage
 6. Transcutaneous electrical nerve stimulation
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treated with radiotherapy or radioablation.11,12,13–17 
A meta-analysis of RCTs found that around 60% of 
patients with uncomplicated bone metastases experi-
enced pain relief in response to external beam radio-
therapy and up to a quarter of these reported complete 
pain relief within 3–4 weeks.38 Use of bisphosphonates 
is recommended11,13–17 and this treatment has a role in 
reducing skeletal morbidity in metastatic disease.39 Bis-
phosphonates may delay the onset of pain but there 
was no evidence of an analgesic effect in a systematic 
review.40 However, a more recent randomised multicen-
tre trial (not included in the systematic review) provided 
good evidence that ibandronate had similar efficacy to 
radiotherapy.41
Support patients to use self-management strate-
gies. Supporting self- management involves helping 
patients make the decision to manage their pain, enhance 
their self-efficacy by solving problems and incorporate 
pain-relieving strategies into daily life.42 Interventions that 
support self-management behaviour are infrequently rec-
ommended by guidelines but evidence shows that they 
are effective in pain control.43–48 Good communication, in 
particular, about opioids is key to maximising patient com-
pliance with and therefore efficacy of treatment.49
Consider physiotherapy-based interventions. Physi-
otherapy and rehabilitation medicine approaches include 
physical exercise (walking and home-based resistance 
exercises), myofascial release and proprioceptive neuro-
muscular facilitation techniques and are associated with 
reduced pain intensity in a pilot RCT, a large randomised 
trial of telerehabilitation, and as a symptom co-existing 
with fatigue.50–52
Non-pharmacological approaches, for example, music 
therapy. Non-pharmacological approaches are recom-
mended.10,11,14,16 Music-based interventions had a sig-
nificant effect on pain intensity based on low-quality 
evidence from seven studies analysed in a Cochrane sys-
tematic review.53 Where no adverse effects have been 
reported, we make a tentative suggestion to consider 
non-pharmacological approaches, such as music therapy, 
as part of a holistic management plan.
Regularly review and evaluate treatment cancer pain treat-
ment outcomes. Multiple guidelines10,11,13,14,15,16 recom-
mend that pain intensity and its management plan should 
be regularly reviewed to assess treatment outcome and 
plan onward care. Moderate evidence shows that review 
and evaluation of cancer pain management at the service 
level improves care and allows comparison between differ-
ent services for example, hospices, community services 
and hospitals.54,55
Practice recommendations – ‘Do not’
Routinely use oral paracetamol to treat moderate or 
severe pain in patients on strong opioids. Paracetamol is 
currently recommended for mild-to-moderate pain in 
guidelines based upon World Health Organization (WHO) 
guidance and the classic ‘cancer pain ladder’.11–13,14,15,16,17 
However, patients with moderate-to-severe cancer pain 
that is already being treated with a strong opioid are 
unlikely to gain any additional benefit. A Cochrane sys-
tematic review found that there is no evidence that using 
paracetamol alone or in combination with opioids is of 
any benefit in treating cancer pain.56 Furthermore, 
Cochrane systematic reviews also find high-quality evi-
dence of no effect compared to placebo in non-cancer 
lower back pain57 and recently osteoarthritis.58 However, 
single-dose intravenous paracetamol is effective in acute 
post-operative pain59 and may offer benefits in acute can-
cer pain, but this needs to be substantiated.
Routinely use weak opioids, such as codeine. Moderate-
quality evidence from a Cochrane systematic review 
shows that there is only a little, low-quality evidence for 
the use of codeine in cancer pain60 and the effectiveness 
of this step only lasts for about a month after which 
patients need to move to a strong opioid to gain sufficient 
analgesia.61 In an open-label RCT of moderate cancer 
pain, low-dose morphine had an earlier and more ade-
quate analgesic effect than weak opioids and a similar tol-
erability.62 Nevertheless, in low resource countries and/or 
where morphine use may be limited, a weak opioid could 
still be a suitable choice for moderate pain.
Routinely use ketamine. Some guidelines include the 
option to use ketamine10,11,14,16 but acknowledge the lack 
of evidence to support its routine use. A Cochrane sys-
tematic review concluded that there was insufficient evi-
dence to determine the benefits and harms of ketamine 
as an adjuvant to opioids.63 Oral ketamine was neither 
superior to placebo in a RCT of patients with cancer-
related neuropathic pain64 nor when used subcutaneously 
as an adjunct to opioids in a randomised, double-blind, 
placebo-controlled study in patients with cancer pain.65 
However, ketamine should not be completely ruled out as 
a third-line approach because of its effectiveness in non-
cancer, acute pain contexts.66,67 Ketamine might be of 
benefit in specific situations, such as patients with central 
sensitisation.68
Routinely use intravenous lidocaine. There is limited data 
that intravenous lidocaine may reduce pain intensity in 
some patients69,70 but a lack of efficacy has been seen in 
other trials.71 Use of lidocaine comes with a risk of fre-
quent adverse effects and therefore specialist supervision 
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is needed. Lidocaine could therefore be considered as an 
option for the treatment of opioid-refractory cancer pain 
as recommended by some guidelines.11,17
Use cannabis-based medicines. Pre-clinical experiments 
show that tetrahydrocannabinol (THC) enhances the 
anti-nociceptive effect of morphine,72 and preliminary 
studies indicated a role as an adjuvant treatment for 
pain in cancer patients.73 However, larger, RCTs of canna-
bis-based drugs as an adjuvant to standard treatment 
in advanced cancer patients have not confirmed any 
benefit.74,75 A recent systematic review76 also concluded 
that very weak evidence suggests no effect of THC or 
oromucosal nabiximols on cancer pain that is not 
relieved by strong opioids.
‘Don’t know’
Further research is needed in patients with moderate and 
severe cancer pain because it is not clear if there is benefit 
of the following.
Non-steroidal anti-inflammatory drugs. Although non-
steroidal anti-inflammatory drugs (NSAIDs) are recom-
mended by guidelines,11–15,17 a Cochrane systematic 
review found that there is no high-quality evidence to 
determine their place in the management of cancer 
pain.77 There is some evidence for a beneficial effect in 
other types of pain78,79 yet considering the potential for 
significant adverse effects, it is important to assess and 
carefully reassess the use of NSAIDs.13 RCT’s evidence is 
urgently needed.
Anti-convulsants, anti-depressants. Despite evidence of 
effectiveness of anti-convulsants and anti-depressants in 
non-cancer contexts,80 there is only very limited evidence 
of efficacy in cancer patients.81 A systematic review and 
meta-analysis found that combining anti-convulsant drugs 
(gabapentin or pregabalin) with opioids did not improve 
pain relief in cancer patients compared with opioids 
alone.82 The authors noted that due to heterogeneity of 
patients, a beneficial effect in some patients with neuro-
pathic pain cannot be discounted. Currently high-quality 
evidence to support their use is lacking and the benefit to 
risk balance is unclear.
Corticosteroids. Multiple current guidelines recom-
mend corticosteroids for some types of cancer 
pain,11,12,14–16 particularly where pain is related to 
inflammation and oedema. Evidence for their efficacy is 
weak, although a Cochrane systematic review found 
that some studies showed a beneficial effect on cancer-
related pain after 1 week of treatment.83 In light of the 
many well-documented adverse effects,84 the likely 
benefit to risk ratio for the individual needs careful 
consideration.
Other anaesthetic interventions. Guidelines recommend 
that nerve blocks, cordotomy and spinal cord stimulation 
are considered in specific situations, such as refractory 
pain11,13,16 or as adjuvant therapy.12 Currently there is not 
enough good-quality evidence to judge whether spinal 
cord stimulation is superior to pharmacological treat-
ments in regards to safety and efficacy for management of 
pain in advanced cancer patients.35,85 RCTs are needed but 
the difficulty of conducting them in the relevant popula-
tion is acknowledged.
Acupuncture, massage. NCCN recommend that massage 
and acupuncture should be considered alongside phar-
macologic interventions.11 Systematic reviews found that 
there is insufficient evidence to recommend the use of 
acupuncture86 or massage87 for relief of pain in cancer 
patients. Patients are often keen to explore complemen-
tary and integrative therapies and report a beneficial 
effect. Considering, the low potential for harm, further 
robust research into the efficacy of complementary thera-
pies should be considered.
Transcutaneous electrical nerve stimulation. Transcuta-
neous electrical nerve stimulation (TENS) is categorised as 
an integrative intervention11 or adjuvant therapy.12 There 
is currently not enough evidence to recommend that 
TENS can be used for cancer pain in general or in advanced 
cancer patients due to a lack of power and undersizing in 
the studies published.88 As a relatively simple, portable, 
non-invasive intervention with high safety profile, TENS 
merits further research in effectiveness trials.
Limitations
Limitations are acknowledged in that as this was a prac-
tice review produced using scoping review methodology, 
a systematic review of the evidence base for each inter-
vention was not performed. There may be additional cur-
rent guidelines and relevant primary literature that we 
have not examined. The source and direction of the evi-
dence, for example, conclusion of the systematic review, 
was considered but the quality of evidence for each origi-
nal study was not re-appraised.
Summary
After comprehensive assessment of the patient, a strong 
opioid remains the drug of choice for treating moderate 
or severe pain in patients with advanced cancer. 
Treatment with bisphosphonates, radiotherapy or both 
for bone pain is effective. Optimal management requires 
a tailored approach, support for self-management and 
regular review of treatment outcomes. Interventions 
commonly recommended by international guidelines 
are not always supported by a robust evidence base. 
Oral paracetamol should not be used in patients already 
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taking a strong opioid to manage moderate or severe 
pain. Cannabis-based drugs are not recommended due 
to evidence of lack of effect. Future research should 
focus on defining the efficacy of NSAIDs, anti-depres-
sants, anti-convulsants, corticosteroids and the likely 
role for non-pharmacological approaches in manage-
ment of pain in patients with advanced cancer. Data are 
needed to support the appropriate selection of patients 
who might benefit from third-line approaches, such as 
lidocaine and ketamine.
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